June 13, 2026

ENDO 2026 Opens in Chicago, Ascendis TransCon PTH 5-Year 82% Response, Crinetics Palsonify 2-Year OLE Sunday, Entera EB613 Oral PTH Late-Breaker, Rusfertide EHA 2026 Long-Term

ENDO 2026 opens with PTH peptide showdown (Ascendis 82% 5-yr, MBX canvuparatide, Entera EB613); Crinetics Palsonify 2-yr OLE Sunday; rusfertide EHA 2026.

5 stories · Covering clinical-trials, industry

Editor's Note

ENDO 2026 opened today in Chicago with the cleanest endocrinology peptide showdown in a decade. Three rival PTH-peptide replacement programs land their long-term reads in the same hall: Ascendis Pharma's TransCon PTH (palopegteriparatide) reported 5-year PaTH Forward data June 11 with 82% of patients off active vitamin D and calcium supplementation at week 266, MBX Biosciences's canvuparatide brought its 12-week + 1-year Avail dataset announced yesterday, and Entera Bio is presenting late-breaking EB613 oral teriparatide data plus a new preclinical EB618 oral GLP-1/glucagon readout. On the somatostatin side, Crinetics presents up to two years of PATHFNDR-1 and PATHFNDR-2 open-label-extension data for once-daily oral Palsonify (paltusotine) on Sunday, with Camurus's Oclaiz now pushed to a potential 2027 US launch after this week's second manufacturing CRL. Chronic hypoparathyroidism, acromegaly, and osteoporosis have stayed dependent on daily injections or monthly intramuscular depots for two decades, and the precision-peptide and oral-peptide platforms behind these readouts are the modalities that could finally change that.

Clinical Trials

Ascendis Pharma 5-Year TransCon PTH PaTH Forward Data: 82% Off Active Vitamin D and Calcium at Week 266, 95% Trial Completion

Ascendis Pharma (Nasdaq: ASND) released June 11 the 5-year (Week 266) results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism, ahead of formal presentation at ENDO 2026 in Chicago. At Week 266, 82% of patients met the composite endpoint of normal serum calcium without active vitamin D and with less than 600 mg/day of calcium; nearly all participants achieved independence from conventional therapy, and 95% completed the full five years. TransCon PTH replicated endogenous PTH across kidney, intestine, CNS, and bone, with normalized urine and serum calcium, sustained bone mineral density, and quality-of-life gains. The data directly stress-tests MBX Biosciences's once-weekly canvuparatide Phase 2 readout from June 12, which posted 63% responder at 12 weeks and 57% at one year.

#ascendis-pharma #transcon-pth #palopegteriparatide #hypoparathyroidism #pth-peptide #endo-2026 #5-year-data

Clinical Trials

Crinetics Palsonify (Paltusotine) Up to 2-Year PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Data at ENDO 2026 on June 14

Crinetics Pharmaceuticals (Nasdaq: CRNX) will present an oral abstract Sunday June 14 (1:45-3:15 PM CT, Room W183BC) covering up to two years of efficacy and pooled safety data from the Palsonify (once-daily oral paltusotine) PATHFNDR-1 and PATHFNDR-2 open-label extensions in acromegaly, plus long-term combination data with cabergoline from the ACROBAT Advance trial. The presentation lands four days after Camurus's second Complete Response Letter on Oclaiz (CAM2029), the rival monthly subcutaneous octreotide depot, leaves the US acromegaly market with only one approved next-generation entrant (Palsonify, approved September 2025) through at least H1 2027. Crinetics will also present six total abstracts at ENDO including Phase 2 atumelnant data in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

#crinetics #palsonify #paltusotine #acromegaly #pathfndr-1 #pathfndr-2 #endo-2026 #open-label-extension

Clinical Trials

Entera Bio EB613 Oral PTH(1-34) Single-Tablet Data Selected for ENDO 2026 Late-Breaking Oral Presentation, EB618 Oral GLP-1/Glucagon NHP PK/PD Saturday

Entera Bio (Nasdaq: ENTX) confirmed that its first-in-class oral PTH(1-34) tablet EB613 was selected for a late-breaking oral presentation at ENDO 2026 covering single-tablet data ahead of the 750-patient Phase 3 trial set to start late 2026 in postmenopausal osteoporosis. EB613 applies Entera's N-Tab oral-peptide delivery platform to teriparatide (the active ingredient in Forteo). On the obesity side, Entera will present preclinical PK/PD data on EB618, a first-in-class oral dual GLP-1/glucagon receptor agonist, in non-human primates on Saturday June 13 12:15-1:45 PM CT. The ENDO slot extends Entera's spring narrative beyond the Q1 2026 Phase 3 plan first disclosed in May.

#entera-bio #eb613 #eb618 #oral-peptide #teriparatide #osteoporosis #endo-2026 #n-tab-platform

Industry

ENDO 2026 Opens in Chicago Through June 16 With 2,500 Abstracts and 7,200 Attendees Across Diabetes, Obesity, Bone, and Rare Endocrine

The Endocrine Society's annual meeting ENDO 2026 opened today at McCormick Place West in Chicago and runs through Tuesday June 16, drawing roughly 7,200 attendees and nearly 2,500 abstracts spanning diabetes, obesity, reproductive health, bone health, endocrine-disrupting chemicals, and thyroid cancer. Saturday's plenary 'Unraveling Hormonal Complexity: Genomics, Sex Differences, and Physiology' features I. Sadaf Farooqi (Cambridge) on single-cell genomics and Holly A. Ingraham (UCSF) on hormones and brain-body physiology. Peptide-anchored programs concentrated in the hypoparathyroidism (Ascendis, MBX, Entera), acromegaly (Crinetics), and oral GLP-1 (Entera EB618 preclinical) tracks; oncology-peptide tracks include OAR-targeted radioligand abstracts and copper-peptide bone-resorption work.

#endo-2026 #endocrine-society #chicago #diabetes #hypoparathyroidism #acromegaly #conference

Clinical Trials

Protagonist and Takeda Bring Phase 3 VERIFY and Long-Term Rusfertide Data to EHA 2026 in Stockholm Through June 14

Protagonist Therapeutics (Nasdaq: PTGX) and Takeda are presenting four rusfertide abstracts at the 2026 European Hematology Association Congress in Stockholm (June 11-14), including analyses from the Phase 3 VERIFY study and long-term results from the Phase 2 REVIVE and THRIVE open-label extensions. The 32-week VERIFY primary analysis showed 76.9% of patients on rusfertide achieved a clinical response versus 32.9% on placebo; the 52-week dataset met the primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class subcutaneous hepcidin-mimetic peptide for polycythemia vera. The FDA accepted the rusfertide NDA in early 2026 with priority review and set a Q3 2026 PDUFA target action date.

#protagonist-therapeutics #takeda #rusfertide #hepcidin #polycythemia-vera #verify-trial #eha-2026 #priority-review